December 2023—Veracyte has entered into a multiyear agreement with Illumina to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic tests on Illumina’s NextSeq 550D× next-generation sequencing instrument. The agreement is part of Veracyte’s expanded, multiplatform IVD approach, which will also include qPCR.
Read More »Home >> Tag Archives: Veracyte
Veracyte, NanoString agreement
January 2020—Veracyte and NanoString have entered into an agreement in which Veracyte has obtained exclusive worldwide rights to develop and commercialize diagnostic tests on NanoString’s nCounter Flex system.
Read More »Veracyte acquires exclusive license to NanoString platform
Dec. 5, 2019—Veracyte and NanoString have entered into an agreement in which Veracyte has obtained exclusive global rights to develop and commercialize diagnostic tests on NanoString’s nCounter Flex system.
Read More »Veracyte, Quest agreement, 5/17
May 2017—Veracyte will extend access to its Afirma Gene Expression Classifier through an agreement with Quest Diagnostics. The agreement is intended to meet growing physician demand for innovative genomic testing services to improve thyroid cancer diagnosis.
Read More »